STAT+: Exemption of rare disease therapies in drug-pricing pilots would wipe out huge savings, analysis finds
↗Exempting orphan (rare-disease) therapies from CMS MFN-style drug-pricing pilots could largely erase expected savings, fueling biotech lobbying to exclude orphan drugs from GLOBE and GUARD.
Aug 5, 20261%